top of page

Global Branded Specialty Business Port-folio Management

  • Insights on ideation of novel branded molecule

    • Disease Modifying Potential

    • 505 (b) (2) route with potentially shortest clinical development

    • Single agents or fixed dose combinations.

    • Oral / Topical / intranasal / systemic Routes

    • Patches / nanoparticles Formulations

    • Targeted treatments in Oncology: McAb-drug conjugates

    • Respiratory, Dermatology, Chronic Pain, Cardio-Metabolic and Oncology therapy areas

  • Scope of clinical differentiation

  • In-licensing opportunities - Scientific Evaluation and due diligence: 

    • Analysis of potential in-licensing opportunities and assets with novel mechanism of action

    • Scientific assessment and insights on first in class and best in class molecules, key differentiation features   

    • Respiratory, Dermatology, Chronic Pain, Oncology and Inflammatory disease areas

    • Broad, targeted, orphan or niche indication

  • Potential Stake Holders: Pharmaceutical, Biotech and Venture Capital companies

bottom of page